LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Список акций・Guardant Health Inc

Guardant Health Inc

Закрыт

СекторЗдравоохранение

130.65 1.14

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

128.45

Макс.

132.96

Ключевые показатели
By Trading Economics
Доход	16M -112M
Продажи	20M 302M
Прибыль на акцию	-0.45
Рентабельность продаж	-37.152
Сотрудники	2,490
EBITDA	18M -101M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+8.32% upside

Дивиденды
By Acuity
Следующий отчет о доходах	29 июл. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	4.6B 17B
Предыдущая цена открытия	129.51
Предыдущая цена закрытия	130.65

Новостные настроения

By Acuity

50%

154 / 344 Рейтинг в Healthcare

Guardant Health Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 июн. 2026 г., 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 июн. 2026 г., 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 июн. 2026 г., 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 июн. 2026 г., 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 июн. 2026 г., 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 июн. 2026 г., 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 июн. 2026 г., 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 июн. 2026 г., 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 июн. 2026 г., 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 июн. 2026 г., 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 июн. 2026 г., 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 июн. 2026 г., 23:38 UTC

Global Equities Roundup: Market Talk

10 июн. 2026 г., 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 июн. 2026 г., 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 июн. 2026 г., 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 июн. 2026 г., 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 июн. 2026 г., 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 июн. 2026 г., 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 июн. 2026 г., 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Financial Services Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Basic Materials Roundup: Market Talk

10 июн. 2026 г., 20:50 UTC

Health Care Roundup: Market Talk

10 июн. 2026 г., 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 июн. 2026 г., 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 июн. 2026 г., 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 июн. 2026 г., 20:33 UTC

Global Equities Roundup: Market Talk

10 июн. 2026 г., 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Сравнение c конкурентами

Изменение цены

Guardant Health Inc Прогноз

Целевая цена

By TipRanks

8.32% рост

Прогноз на 12 месяцев

Средняя 140.94 USD 8.32%

Максимум 175 USD

Минимум 120 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Guardant Health Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

19 ratings

Покупка

Удержание

Продажа

Основано на мнении 19 аналитиков, присваивавших рейтинги акциям Guardant Health Inc – Данные за последние 3 месяца.

Настроения

By Acuity

154 / 344Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.